Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328793 | 0.85 | DRD4 (0.37) | ALDH1A1TP53DRD4MAPTHPGD | |
| SCHEMBL26750381 | 0.84 | ALDH1A1 (0.58) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL11749561 | 0.81 | AR (0.50) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL11761868 | 0.81 | AR (0.47) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL6618622 | 0.80 | ALDH1A1 (0.57) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL7059201 | 0.80 | ALDH1A1 (0.47) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL28227853 | 0.79 | ALDH1A1 (0.44) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL3354399 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL4177996 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL17885761 | 0.77 | ALDH1A1 (0.50) | ALDH1A1GLATDP1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | ALDH1A1 2649/4885GLA 111/4885TDP1 504/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | ALDH1A1 2584/4885GLA 157/4885TDP1 490/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | ALDH1A1 2784/4885GLA 233/4885TDP1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.